Dermata shareholders approve warrant issuance and auditor ratification at special meeting

Dermata Therapeutics, Inc.

Issuance Proposal: 789,001 for, 5,008 against, 231 abstain, 485,871 broker non-votes — approved.
Ratification of Moss Adams LLP as independent auditor for FY 2023: 1,269,895 for, 9,551 against, 665 abstain — approved.
Adjournment Proposal: 788,925 for, 4,893 against, 422 abstain, 485,871 broker non-votes — approved.
Special meeting held January 12, 2024; record date November 17, 2023 with 3,189,034 shares outstanding.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Dermata Therapeutics, Inc. shareholders approved The ratification of the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 (Auditor Proposal) at the 2024-01-12 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2024-01-12

Exact text from the filing

Proposal No. 2 : The Auditor Proposal was approved by a vote of stockholders as follows: Votes For Votes Against Abstentions Broker Non-Votes 1,269,895 9,551 665 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Dermata Therapeutics, Inc. shareholders approved The authorization for purposes of complying with Nasdaq Listing Rule 5635(d) of the issuance of shares of Common Stock underlying certain warrants (Issuance Proposal) at the 2024-01-12 meeting.

Outcome: passed
Meeting: 2024-01-12

Exact text from the filing

Proposal No. 1 : The Issuance Proposal was approved by a vote of stockholders as follows: Votes For Votes Against Abstentions Broker Non-Votes 789,001 5,008 231 485,871

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Dermata Therapeutics, Inc. shareholders approved The approval of the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies (Adjournment Proposal) at the 2024-01-12 meeting.

Outcome: passed
Meeting: 2024-01-12

Exact text from the filing

Proposal No. 3 : The Adjournment Proposal was approved by a vote of stockholders as follows: Votes For Votes Against Abstentions Broker Non-Votes 788,925 4,893 422 485,871

View on SEC.gov

Browse all shareholder votes →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-000520

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.